.png/:/rs=w:400,cg:true,m)
Both SpayVac-pZP and SpayVac-GnRH prevented pregnancy in bison cows in 1st year of trial
October 26, 2026. In partnership with the Turner Institute of Ecoagriculture, SpayVac initiated a study in December 2025 to compare the effectiveness of single-dose, long-lasting pZP- and GnRH-based SpayVac vaccines against a control group in preventing pregnancies in young female bison for at least two years. Thirty bison were recently checked using ultrasound to determine pregnancy status, and the results are promising. None of the ten pZP-treated females were found to be pregnant and only one of ten GnRH-treated females was pregnant, compared to nine of ten untreated bison (p<0.001). This is the first time that SpayVac has been tested in a bovid species, having performed well previously in numerous equid and cervid species, as well as seals and elephants. The study will continue for at least another year and is envisioned to provide a useful management tool for bison producers.
SpayVac and Turner Institute Partner on Multi-Year Bison Contraceptive Vaccine Study
August 18, 2026. SpayVac has partnered with the Turner Institute of Ecoagriculture to test the contraceptive efficacy of two vaccine formulations in female bison. The study is planned to continue for multiple years with annual antibody titer assessments and pregnancy checks. Learn more on our partner’s website.
SpayVac Sponsors International Wildlife Fertility Control Conference in Barcelona
April 23-24, 2026. SpayVac was proud to be a Platinum-Level Sponsor of the 10th International Conference on Wildlife Fertility Control, hosted by the Botstiber Foundation in Barcelona, Spain in April 2026. Dr. Ursula Bechert presented on the role of deer contraception as both a practical management tool and a long-term conservation strategy — including its importance in reducing tick-borne disease risks in growing deer populations. The event brought together 100+ researchers, wildlife managers, and partners from 23 countries across six continents.
Thailand Uses Contraceptive Vaccine to Manage Elephant Population
January 26, 2026. In a collaborative study with Chiang Mai University and the Thailand Department of National Parks, a small group of female wild elephants was vaccinated to control the population size and promote sustainable coexistence between humans and elephants. Animals will be monitored for multiple years to assess contraceptive efficacy. https://world.thaipbs.or.th/detail/60275 and https://www.youtube.com/watch?v=XFtmBIiFaLw.
Positive Efficacy Data Supports Broader Application of Spayvac® pZP in Deer Populations
October 14, 2025. Results from a study of deer in the Bavarian National Park show SpayVac® safely and effectively reduces deer fertility with a single vaccination, advancing humane population control strategies for ecosystems facing pressure from population growth. https://link.springer.com/article/10.1007/s10344-025-01988-3.
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE INC. EXPAND LICENSING AGREEMENT INTO COMMERCIAL AQUACULTURE
April 22, 2025. We’re excited to announce that our license agreement with BioVaxys (BVAXF U.S.: OTC) has been expanded to include commercial rights in aquaculture. This marks an important step forward as we build on successful proof-of-concept trials in farm-raised salmon and trout and prepare for dose-optimization studies in collaboration with our partners. https://www.prnewswire.com/news-releases/biovaxys-and-spayvac-for-wildlife-expand-license-agreement-into-commercial-aquaculture-302434429.html
SpayVac Continues to Scale-Up Vaccine Production Capacity at Our Madison Facility
November 20, 2024. SpayVac continues to gain traction. We are proud to announce that we have shipped a batch of vaccines from our Madison laboratory to Europe. This is a significant milestone as we've shipped to North America, Asia and Europe from our Madison location this year. PRN news wire link: https://www.prnewswire.com/news-releases/biovaxys-partner-spayvac-for-wildlife-inc-scales-up-vaccine-production-capacity-302311055.html
CEO Corner Video About SpayVac
September 05, 2024. SpayVac CEO, Tom D'Orazio, discusses where the company is, how the product works, and the abundant opportunities and needs for their unique product.
Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry
April 10, 2024. SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immunocontraceptive vaccines in farmed rainbow trout.